HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (37) Citing Articles via Google Scholar Google Scholar Articles by Field, S. K. Articles by Cowie, R. L. Search for Related Content PubMed PubMed Citation Articles by Field, S. K. Articles by Cowie, R. L.

Mycobacterium avium complex Pulmonary Disease in Patients Without HIV Infection^*

^* From the Division of Respiratory Medicine, University of Calgary Medical School, Calgary, AB, Canada.

Correspondence to: Stephen K. Field, MD, FCCP, Room 1410, Health Science Centre, 3330 Hospital Dr NW, Calgary, AB, Canada T2N 4N1; e-mail sfield{at}ucalgary.ca

Mycobacterium avium complex (MAC) is ubiquitous. It is found in various freshwater and saltwater sources around the world, including hot water pipes. Although the organism was identified in the 1890s, its potential to cause human disease was only recognized 50 years later. Only a minority of people exposed to the organism will acquire MAC lung disease, usually those with underlying lung disease or immunosuppression. MAC may, however, cause progressive parenchymal lung disease and bronchiectasis in patients without underlying lung disease, particularly in middle-aged and elderly women. Preliminary data suggest that the interferon- pathways may be deficient in elderly women with MAC lung disease. Other groups of patients who are more likely to harbor MAC in their lungs include patients with a cystic fibrosis or an abnormal ₁-antiproteinase gene and patients with certain chest wall abnormalities. Treatment results continue to be disappointing, and the mortality of patients with MAC lung disease remains high. A PubMed search identified 38 reports of the treatment of MAC lung disease. Apart from the British Thoracic Society study, the only published controlled investigation, the studies published since 1994 have included a macrolide, either clarithromycin or azithromycin, usually in combination with ethambutol and a rifamycin. If success is defined as eradication of the organism without relapse over a period of several years after treatment has been discontinued, the reported treatment success rate with the macrolide containing regimens is approximately 55%. The prolonged treatment period, side effects, and possibly reinfection rather than relapse are responsible for the high failure rate.

Key Words: bronchiectasis • clarithromycin • ethambutol • macrolides • Mycobacterium avium • Mycobacterium intracellulare • nontuberculous mycobacteria • rifabutin rifampin

This article has been cited by other articles:

				E. A. Waller, A. Roy, L. Brumble, A. Khoor, M. M. Johnson, and J. L. Garland The Expanding Spectrum of Mycobacterium avium Complex-Associated Pulmonary Disease. Chest, October 1, 2006; 130(4): 1234 - 1241. [Abstract] [Full Text] [PDF]

				M. P. Pietila, P. K. Vohra, B. Sanyal, N. L. Wengenack, S. Raghavakaimal, and C. F. Thomas Jr. Cloning and Characterization of CYP51 from Mycobacterium avium Am. J. Respir. Cell Mol. Biol., August 1, 2006; 35(2): 236 - 242. [Abstract] [Full Text] [PDF]

				P. K. Lam, D. E. Griffith, T. R. Aksamit, S. J. Ruoss, S. M. Garay, C. L. Daley, and A. Catanzaro Factors Related to Response to Intermittent Treatment of Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., June 1, 2006; 173(11): 1283 - 1289. [Abstract] [Full Text] [PDF]

				W.-J. Koh, O. J. Kwon, K. Jeon, T. S. Kim, K. S. Lee, Y. K. Park, and G. H. Bai Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest, February 1, 2006; 129(2): 341 - 348. [Abstract] [Full Text] [PDF]

				M Wickremasinghe, L J Ozerovitch, G Davies, T Wodehouse, M V Chadwick, S Abdallah, P Shah, and R Wilson Non-tuberculous mycobacteria in patients with bronchiectasis Thorax, December 1, 2005; 60(12): 1045 - 1051. [Abstract] [Full Text] [PDF]

				W.-J. Koh, O. J. Kwon, E. J. Kim, K. S. Lee, C.-S. Ki, and J. W. Kim NRAMP1 Gene Polymorphism and Susceptibility to Nontuberculous Mycobacterial Lung Diseases Chest, July 1, 2005; 128(1): 94 - 101. [Abstract] [Full Text] [PDF]

				J. Reich, S. K. Field, D. Fisher, and R. L. Cowie Treatment Outcome in Mycobacterium avium Pulmonary Disease: A Correction and Comment Chest, May 1, 2005; 127(5): 1864 - 1866. [Full Text] [PDF]